The list the FDA published last week is not likely to cause broader damage to the reputations of companies named, experts say.

With new nods for Pfizer’s Xeljanz and AbbVie’s upadacitinib coming, makers of anti-inflammatory drugs will be feeling the heat from JAK inhibitors.

Roche's Hemlibra, on its way to treating a much wider population, put up some big data over the weekend that should back its bid at FDA.

Lokelma moved past two rejections to win its nod, and now it's ready to tackle Vifor's hyperkalemia rival Veltassa, approved back in 2015.

The FDA has OK’d the Daewoong manufacturing plant that will make Evolus’ Botox rival but rejected Evolus' biologic over its manufacturing design.

The One Show’s return to health and pharma recently resulted in a slew of creative awards, but only one of them went to an actual drugmaker.

An ad within an ad is the theme of AstraZeneca’s first DTC campaign for Fasenra.

The copay coupon fight is getting hotter than ever.

AbbVie tried to replace its Imbruvica formula with a single-pill version that cost three times as much for some patients. That didn't go over well.